INSP Stock Forecast & Price Target

Inspire Medical Systems has demonstrated significant growth in its workforce, with employee numbers rising to 1,333 at year-end 2025, marking an increase from 1,246 in 2024, which reflects the company's expanding operational capabilities. The company has also increased its advertising expenses by 21% year-over-year to $114.9 million in 2025, indicating a robust commitment to expanding its market presence and promoting its innovative Inspire system for obstructive sleep apnea. Furthermore, Inspire is projected to sustain a double-digit growth trajectory, supported by healthy gross margins exceeding 80% and improving profitability as management anticipates year-over-year revenue growth and profitable outcomes later in the fiscal year.

Inspire Medical Systems Inc has lowered its revenue guidance for FY 2026 from $1,003-1,013 million to $950-1,000 million, primarily due to reimbursement uncertainties and changes in coding that may dissuade ENT specialists from performing necessary procedures. The company is facing significant headwinds in its growth trajectory as the domestic market shows signs of deceleration, compounded by rising concerns regarding reimbursement levels and a complicated roll-out of new initiatives like the WISeR program. These factors have created an environment where a reassessment of the company's valuation seems warranted, leading to a negative outlook on its stock performance.